Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Zonisamide Might Have Neuroprotective Effects
March 23, 2009
- Gilead Sciences to Acquire CVT
March 23, 2009
- LDP Diet Members Inaugurate Federation on Online Sale of Drugs
March 23, 2009
- Novartis Launches 4 New Drugs at Same Time
March 23, 2009
- More Time Needed to Ensure Safety of Drugs Sold Online: Council
March 23, 2009
- DSP to Promote Trerief as 3rd-Line Anti-Parkinson Drug
March 23, 2009
- Ban on Online Sale of Drugs Runs Counter to the Constitution: JODA
March 23, 2009
- BUSINESS NEWS IN BRIEF
March 23, 2009
- Counterfeit Drugs Will Pour In if Online Sale Is Freed: Ms Tokashiki
March 23, 2009
- Guidance for Biosimilars Issued
March 23, 2009
- MEDICAL DEVICE NEWS IN BRIEF
March 23, 2009
- JGA to Improve Its Generics Information Supply System
March 23, 2009
- Why Outsourcing Is the "in" Thing
March 23, 2009
- Savings Notification Services Effective to Promote Use of Generics
March 23, 2009
- Only 30% of Doctors Use Recommended Standard Chemotherapy Regimens
March 23, 2009
- JSGM to Determine Measures to Further Promote Use of Generics
March 23, 2009
- 30% of Asthma Patients Take Oral Steroids: Patient Group Survey
March 23, 2009
- Nat'l Univ. Hospitals to Consider Joint Purchase of Drugs
March 16, 2009
- New Sales System May Adversely Affect Business in Short Term: Mr Yamada of Rohto
March 16, 2009
- BUSINESS NEWS IN BRIEF
March 16, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…